Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.

Cancer Immunol Immunother · 2021 · PMC8195930 · PMID 33420629

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

showed a trendp = 0.075so close (0.05 < p ≤ 0.1)

After accounting for patient demographic and clinical characteristics, the multivariable CPH model showed that increased clonality showed a trend toward decreased OS (HR = 2.79 with 95% CI [0.90, 8.66], p = 0.075), though not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.